In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,

Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans, and reducing prices for certain dosages.

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells.

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their insurance. Novo Nordisk is now discounting Wegovy for cash customers too.

Eli Lilly is partnering with Imagine Entertainment and MACRO to drive industry-wide change and guide in authentically representing disease.

Eli Lilly and Company (NYSE: LLY ... for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea ...

Obesity drugs, durable revenue bringing Big Money investors to Eli Lilly and Company (LLY).

Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie and Eli Lilly strike mid-sized deals in obesity and molecular glues, priority review vouchers set to take a hit and immuno-oncology matures.

Novo Nordisk (NVO) stock in focus as company launches its direct-to-consumer platform NovoCare Pharmacy for Wegovy delivery. Read more here.

Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical ... In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks ...